{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:53:30Z","timestamp":1782906810392,"version":"3.54.5"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>After first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), 20\u201330% of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed or refractory disease. Semi-quantitative volume parameters on [18F]Fluorodeoxyglucose positron emission tomography\/computed tomography ([18F]FDG PET\/CT), performed at diagnosis, could represent variables with prognostic influence. We retrospectively analyzed 53 consecutive patients, treated between 2016 and 2022. Semi-quantitative metabolic parameters, assessed by the software LIFEx, included total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), Dmax and DmaxVox. All cases received R-CHOP\/CHOP-like regimens with curative intent. The International Metabolic Prognostic Index (IMPI) was low in 43\/53 cases (81.1%). CR was achieved in 49\/53 patients (92.4%); 7\/53 (13.2%) relapsed after achieving a CR. For the entire cohort, 2-year PFS and OS were 84.9% and 90.6%, respectively, while 5-year PFS and OS were 65.5% and 77.6%, respectively. IPI score, B symptoms, TMTV, Dmax and DmaxVox were associated with reduced PFS in an exploratory univariate analysis. IPI score was the only variable for which we found a significant association with reduced OS. In this exploratory analysis in a small, event-limited population, we suggest the baseline, semi-quantitative metabolic parameters of PET\/CT at diagnosis could contribute to defining tumor burden and to predict PFS for DLBCL patients.<\/jats:p>","DOI":"10.3390\/curroncol33070392","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:19:02Z","timestamp":1782893942000},"page":"392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Semi-Quantitative Metabolic Parameters on [18F]FDG PET\/CT in Patients with Diffuse Large B-Cell Lymphoma at Diagnosis"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0432-9706","authenticated-orcid":false,"given":"Emanuele","family":"Cencini","sequence":"first","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Orsini","sequence":"additional","affiliation":[{"name":"Unit of Nuclear Medicine, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Franceschini","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fredducci","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Bello","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Pacini","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Bradaschia","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-2956","authenticated-orcid":false,"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Carrara","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bertelli","sequence":"additional","affiliation":[{"name":"Unit of Nuclear Medicine, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-3913","authenticated-orcid":false,"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-9715","authenticated-orcid":false,"given":"Alberto","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Unit of Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: Population-level projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e3202","DOI":"10.1002\/hon.3202","article-title":"Diffuse large B-cell lymphoma","volume":"42","author":"Barraclough","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bjh.19273","article-title":"The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline","volume":"204","author":"Fox","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3324\/haematol.2022.281407","article-title":"Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: A report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)","volume":"108","author":"Tucci","year":"2023","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/bjh.20129","article-title":"Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline","volume":"206","author":"Chaganti","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1007\/s00277-025-06686-3","article-title":"Diffuse large B-cell lymphoma in the new era: Prognostic tools for mapping risk","volume":"104","author":"Duminuco","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.5858\/arpa.2024-0366-OA","article-title":"The Impact of Scoring Method on Accuracy and Reproducibility of Hans Cell-of-Origin Prediction in Excisional Biopsies of Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","volume":"149","author":"Yanko","year":"2025","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105630","DOI":"10.1016\/j.humpath.2024.105630","article-title":"Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm","volume":"151","author":"Maeshima","year":"2024","journal-title":"Hum. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","article-title":"PET\/CT in Non-Hodgkin Lymphoma: An Update","volume":"53","author":"Zanoni","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.semnuclmed.2017.09.003","article-title":"PET\/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma","volume":"48","author":"Kobe","year":"2018","journal-title":"Semin. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","article-title":"Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: A systematic review","volume":"48","author":"Frood","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/10428194.2018.1562181","article-title":"PET-derived tumor metrics predict DLBCL response and progression-free survival","volume":"60","author":"Islam","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s00277-023-05336-w","article-title":"Prediction nomogram based on 18F-FDG PET\/CT and clinical parameters for patients with diffuse large B-cell lymphoma","volume":"102","author":"Peng","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1395824","DOI":"10.3389\/fonc.2024.1395824","article-title":"Baseline and interim (18)F-FDG PET\/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma","volume":"14","author":"Liao","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12149-020-01531-1","article-title":"Prognostic value of the baseline 18F-FDG PET\/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL","volume":"35","author":"Zhao","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"99587","DOI":"10.18632\/oncotarget.20447","article-title":"Prognostic significance of total metabolic tumor volume on (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","article-title":"Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study","volume":"107","author":"Kostakoglu","year":"2022","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1565525","DOI":"10.3389\/fmed.2025.1565525","article-title":"Prognostic value of a simple distance index derived from PET maximum intensity projection","volume":"12","author":"Gheysens","year":"2025","journal-title":"Front. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2967\/jnumed.124.267789","article-title":"International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline (18)F-FDG PET\/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation","volume":"65","author":"Boellaard","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"994520","DOI":"10.3389\/fimmu.2023.994520","article-title":"Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers","volume":"14","author":"Choi","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Cottereau, A.S., Meignan, M., Nioche, C., Clerc, J., Chartier, L., Vercellino, L., Casasnovas, O., Thieblemont, C., and Buvat, I. (2021). New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET\/CT. Cancers, 13.","DOI":"10.3390\/cancers13163998"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1007\/s00259-025-07176-4","article-title":"Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials","volume":"52","author":"Malmon","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/cancers15092494","article-title":"(18)F-FDG PET\/CT Maximum Tumor Dissemination (Dmax) in Lymphoma: A New Prognostic Factor?","volume":"15","author":"Albano","year":"2023","journal-title":"Cancers"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_29","first-page":"1876","article-title":"International Metabolic Prognostic Index Is Superior to Other Metabolic Tumor Volume-Based Prognostication Methods in a Real-Life Cohort of Diffuse Large B-Cell Lymphoma","volume":"65","author":"Vergote","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/bloodadvances.2023012165","article-title":"Real-world applicability of the International Metabolic Prognostic Index in DLBCL: A validation cohort study","volume":"8","author":"Ikeda","year":"2024","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.2967\/jnumed.121.263067","article-title":"The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in (18)F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma","volume":"63","author":"Driessen","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/bloodadvances.2023009839","article-title":"A Fondazione Italiana Linfomi cohort study of R-COMP vs. R-CHOP in older patients with diffuse large B-cell lymphoma","volume":"7","author":"Arcari","year":"2023","journal-title":"Blood Adv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1080\/10428194.2020.1755859","article-title":"Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma","volume":"61","author":"Merli","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","article-title":"Prognostic indices in diffuse large B-cell lymphoma: A population-based comparison and validation study of multiple models","volume":"13","author":"Jelicic","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/16078454.2022.2147916","article-title":"External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival","volume":"27","author":"Warnnissorn","year":"2022","journal-title":"Hematology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.01.010","article-title":"High total metabolic tumor volume in PET\/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era","volume":"42","author":"Song","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular Profile and FDG-PET\/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell\u2002Lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s00259-017-3907-x","article-title":"Combination of baseline FDG PET\/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma","volume":"45","author":"Toledano","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12032-014-0446-1","article-title":"Predictive value of F-18 FDG PET\/CT quantization parameters in diffuse large B cell lymphoma: A meta-analysis with 702 participants","volume":"32","author":"Xie","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e70207","DOI":"10.1002\/hem3.70207","article-title":"Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up","volume":"9","author":"Thieblemont","year":"2025","journal-title":"Hemasphere"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","article-title":"SAKK38\/07 study: Integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model","volume":"4","author":"Ceriani","year":"2020","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"key":"ref_49","first-page":"272","article-title":"Baseline total lesion glycolysis measured with (18)F-FDG PET\/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: A pilot study","volume":"3","author":"Esfahani","year":"2013","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1002\/cam4.2284","article-title":"A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %deltaSUV(max)","volume":"8","author":"Zhang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Guo, B., Tan, X., Ke, Q., and Cen, H. (2019). Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210224"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/cancers15102753","article-title":"Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma","volume":"15","author":"Perrone","year":"2023","journal-title":"Cancers"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hon.3081","article-title":"The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi","volume":"41","author":"Cencini","year":"2023","journal-title":"Hematol. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:33:52Z","timestamp":1782905632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/7\/392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["curroncol33070392"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33070392","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}